BioCentury | Jul 31, 2019
Company News

Apelian to lead new T cell company BlueSphere

...in May. Before his tenure there, he was CMO of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and GlobeImmune Inc....
BioCentury | Nov 18, 2016
Company News

Gilead ends GlobeImmune HBV deal

...2011 partnership to develop HBV vaccines. The companies had hoped to create vaccines based on GlobeImmune's...
...cerevisiae genetically modified to express a disease-associated antigen (see BioCentury Extra, Oct. 24, 2011) . GlobeImmune...
..."open to repartnering" the program. GlobeImmune sank $0.29 (42%) to $0.40 on Friday. Becky Simon GS-4774 Gilead Sciences Inc. GlobeImmune Inc....
BioCentury | Nov 18, 2016
Company News

Gilead, GlobeImmune deal

...GlobeImmune said Gilead terminated a 2011 deal granting Gilead rights to GS-4774 . GlobeImmune regained all...
...trial to treat chronic HBV infection. The biotech restructured shortly thereafter. Gilead referred inquiries to GlobeImmune...
...Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GlobeImmune Inc. (Pink:GBIM), Louisville, Colo. Business: Infectious Alicia Parker GS-4774 Gilead Sciences Inc. GlobeImmune Inc....
BioCentury | Sep 21, 2015
Company News

GlobeImmune cancer news

...In August, GlobeImmune hired Cantor Fitzgerald & Co. to evaluate strategic options, including a merger or...
...option under an 2009 deal and received exclusive, worldwide rights to cancer product GI-6207 from GlobeImmune...
...therapy is a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses carcinoembryonic antigen (CEA) . GlobeImmune...
BioCentury | Aug 10, 2015
Company News

GlobeImmune, Celgene deal

...under an 2009 deal and received exclusive, worldwide rights to oncology candidate GI-6207 from GlobeImmune. GlobeImmune...
...therapy is a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses carcinoembryonic antigen (CEA) . GlobeImmune...
...expects data in 2H16 from a Phase II trial to treat medullary thyroid cancer (MTC). GlobeImmune...
BioCentury | Aug 4, 2015
Company News

Celgene licenses GlobeImmune cancer candidate

...oncology candidate GI-6207 from GlobeImmune Inc. (NASDAQ:GBIM). The therapy targets cancers that express carcinoembryonic antigen (CEA). GlobeImmune...
...expects results in 2H16 from a Phase II trial to treat medullary thyroid cancer (MTC). GlobeImmune...
...GlobeImmune $40 million up front and received an equity stake. In 2013, Celgene licensed another GlobeImmune...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

...should fund operations through June 30, 2016. 6/10/15 GlobeImmune Inc. (NASDAQ:GBIM) NA $14.4 2.25 3/31/15 $1.6 GlobeImmune...
...a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses HBV antigens. At Dec. 31, 2014, GlobeImmune...
BioCentury | Jun 15, 2015
Company News

GlobeImmune infectious news

...Phase II GS-US-330-0101 trial to treat chronic HBV infection in May. At Dec. 31, 2014, GlobeImmune...
...also in a Phase II trial in treatment-naive patients with HBV infection. At March 31, GlobeImmune...
...NASDAQ:CELG, Summit, N.J.) has an exclusive license to GlobeImmune’s GI-6300 program, including GI-6301. In 2011, GlobeImmune...
BioCentury | Jun 15, 2015
Clinical News

GI-6301: Phase II started

...exclusive license to GlobeImmune’s GI-6300 program, including GI-6301. GlobeImmune received a $9 million exercise payment. GlobeImmune...
...for tiered royalties ranging from single digits to low double-digits. Celgene Corp. (NASDAQ:CELG), Summit, N.J. GlobeImmune Inc....
BioCentury | Jun 1, 2015
Clinical News

GS-4774: Phase II data

...is also in a Phase II trial in treatment-naive patients with HBV infection. In 2011, GlobeImmune...
...suppressive antiviral therapies (see BioCentury, Oct. 31, 2011). Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GlobeImmune Inc....
Items per page:
1 - 10 of 103
BioCentury | Jul 31, 2019
Company News

Apelian to lead new T cell company BlueSphere

...in May. Before his tenure there, he was CMO of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and GlobeImmune Inc....
BioCentury | Nov 18, 2016
Company News

Gilead ends GlobeImmune HBV deal

...2011 partnership to develop HBV vaccines. The companies had hoped to create vaccines based on GlobeImmune's...
...cerevisiae genetically modified to express a disease-associated antigen (see BioCentury Extra, Oct. 24, 2011) . GlobeImmune...
..."open to repartnering" the program. GlobeImmune sank $0.29 (42%) to $0.40 on Friday. Becky Simon GS-4774 Gilead Sciences Inc. GlobeImmune Inc....
BioCentury | Nov 18, 2016
Company News

Gilead, GlobeImmune deal

...GlobeImmune said Gilead terminated a 2011 deal granting Gilead rights to GS-4774 . GlobeImmune regained all...
...trial to treat chronic HBV infection. The biotech restructured shortly thereafter. Gilead referred inquiries to GlobeImmune...
...Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GlobeImmune Inc. (Pink:GBIM), Louisville, Colo. Business: Infectious Alicia Parker GS-4774 Gilead Sciences Inc. GlobeImmune Inc....
BioCentury | Sep 21, 2015
Company News

GlobeImmune cancer news

...In August, GlobeImmune hired Cantor Fitzgerald & Co. to evaluate strategic options, including a merger or...
...option under an 2009 deal and received exclusive, worldwide rights to cancer product GI-6207 from GlobeImmune...
...therapy is a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses carcinoembryonic antigen (CEA) . GlobeImmune...
BioCentury | Aug 10, 2015
Company News

GlobeImmune, Celgene deal

...under an 2009 deal and received exclusive, worldwide rights to oncology candidate GI-6207 from GlobeImmune. GlobeImmune...
...therapy is a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses carcinoembryonic antigen (CEA) . GlobeImmune...
...expects data in 2H16 from a Phase II trial to treat medullary thyroid cancer (MTC). GlobeImmune...
BioCentury | Aug 4, 2015
Company News

Celgene licenses GlobeImmune cancer candidate

...oncology candidate GI-6207 from GlobeImmune Inc. (NASDAQ:GBIM). The therapy targets cancers that express carcinoembryonic antigen (CEA). GlobeImmune...
...expects results in 2H16 from a Phase II trial to treat medullary thyroid cancer (MTC). GlobeImmune...
...GlobeImmune $40 million up front and received an equity stake. In 2013, Celgene licensed another GlobeImmune...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

...should fund operations through June 30, 2016. 6/10/15 GlobeImmune Inc. (NASDAQ:GBIM) NA $14.4 2.25 3/31/15 $1.6 GlobeImmune...
...a Tarmogen comprising a heat-inactivated Saccharomyces cerevisiae that expresses HBV antigens. At Dec. 31, 2014, GlobeImmune...
BioCentury | Jun 15, 2015
Company News

GlobeImmune infectious news

...Phase II GS-US-330-0101 trial to treat chronic HBV infection in May. At Dec. 31, 2014, GlobeImmune...
...also in a Phase II trial in treatment-naive patients with HBV infection. At March 31, GlobeImmune...
...NASDAQ:CELG, Summit, N.J.) has an exclusive license to GlobeImmune’s GI-6300 program, including GI-6301. In 2011, GlobeImmune...
BioCentury | Jun 15, 2015
Clinical News

GI-6301: Phase II started

...exclusive license to GlobeImmune’s GI-6300 program, including GI-6301. GlobeImmune received a $9 million exercise payment. GlobeImmune...
...for tiered royalties ranging from single digits to low double-digits. Celgene Corp. (NASDAQ:CELG), Summit, N.J. GlobeImmune Inc....
BioCentury | Jun 1, 2015
Clinical News

GS-4774: Phase II data

...is also in a Phase II trial in treatment-naive patients with HBV infection. In 2011, GlobeImmune...
...suppressive antiviral therapies (see BioCentury, Oct. 31, 2011). Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GlobeImmune Inc....
Items per page:
1 - 10 of 103